
Former director of Chinook Therapeutics, Rouzbeh 'Ross' Haghighat, has been convicted alongside several others for misusing material non-public information related to a $3.2 billion merger with Novartis, which led to illicit profits exceeding $600,000.
A federal jury in New Jersey found four individuals guilty on charges of insider trading. The US Securities and Exchange Commission (SEC) also filed civil insider trading charges against Haghighat, his family members, and close friends in August, alleging they purchased securities ahead of the public announcement of the Chinook acquisition by Novartis.